Market Research Report
Asia Pacific Crispr Market Forecast 2019-2027
|Published by||Inkwood Research||Product code||410549|
|Published||Content info||91 Pages
Delivery time: 2-3 business days
|Asia Pacific Crispr Market Forecast 2019-2027|
|Published: December 10, 2018||Content info: 91 Pages||
The revenue generated by the Asia-Pacific CRISPR market is expected to multiply over the forecast period of 2019-2027, due to an expected CAGR of 33.84%. CRISPR majorly finds its applications in industries like agriculture and animal breeding for this region.
China, Japan, and India are some of the major markets contributing to the Asia-Pacific CRISPR market. The Japanese CRISPR market contributed the highest revenue share in 2018, but it is the South Korea market that is expected to progress with the highest CAGR over the forecast period. However, even though more and more research on GMOs is being performed in the Asia-Pacific region, people are still concerned about the undiscovered side effects and unanticipated adverse effects of the CRISPR technology on the environment. Also, possible misuse of CRISPR gene editing tools is another major factor hindering the market growth.
Intellia Therapeutics Inc, Caribou Biosciences Inc, Cellectis Bioresearch Sas, Integrated DNA Technologies (IDT), Crispr Therapeutics Ag,Genscript, Novartis International Ag, Editas Medicine, Transposagen Biopharmaceuticals Inc, Sigma-Aldrich (Merck), Precision Biosciences and Thermo Fisher Scientific are some of the established players in this market.